INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
October 16, 2023 09:00 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 16, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage...
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
September 07, 2023 09:00 ET
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight...
INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease
September 05, 2023 08:00 ET
|
INmune Bio, Inc.
The authorization provides approval for the Company to expand the ongoing Phase 2 trial of XPro™ in patients with early Alzheimer’s disease to the U.K. Boca Raton, Florida, Sept. 05, 2023 ...
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
August 07, 2023 16:00 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
August 01, 2023 08:00 ET
|
INmune Bio, Inc.
Boca Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight...
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
July 31, 2023 08:00 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
July 12, 2023 08:00 ET
|
INmune Bio, Inc.
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca Raton, Florida, July 12, 2023 ...
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
July 11, 2023 08:00 ET
|
INmune Bio, Inc.
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM ...
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
July 10, 2023 16:00 ET
|
INmune Bio, Inc.
Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE...
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
May 24, 2023 09:00 ET
|
INmune Bio, Inc.
Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening Session BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announces that Mark...